RIGL Q1 2019 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M

Gross Profit

$13M99.2% margin

Operating Income

-$18M-145.6% margin

Net Income

-$18M-139.4% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

-66.7%

Cash Flow

Operating Cash Flow

-$569,000

Free Cash Flow

-$946,000

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$173M

Total Liabilities

$77M

Stockholders' Equity

$95M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$0	—
Gross Profit	$13M	-$11M	+211.3%
Operating Income	-$18M	-$25M	+25.7%
Net Income	-$18M	-$24M	+27.8%

Revenue Segments

Gross Product

$10M39%

Product

$8M32%

Contract Revenues From Collaborations

$5M18%

License

$4M18%

Research And Development Services

$71,0000%

Discounts And Allowances

-$2M-7%